Rosiglitazone Reduces Acylation Stimulating Protein Production in Type 2 Diabetics
Author Information
Author(s): Tahiri Youssef, Karpe Fredrik, Tan Garry D, Cianflone Katherine
Primary Institution: Medicine, McGill University, Montreal, Canada
Hypothesis
Does rosiglitazone treatment alter the postprandial production of acylation stimulating protein (ASP) and its precursor C3 in type 2 diabetic men compared to healthy non-obese men?
Conclusion
Rosiglitazone treatment decreases postprandial production of acylation stimulating protein in type 2 diabetics.
Supporting Evidence
- Postprandial arterial triglycerides and non-esterified fatty acids were higher in diabetics compared to controls.
- Rosiglitazone treatment significantly decreased postprandial glucose and insulin concentrations in diabetics.
- Increased postprandial venous production of ASP was specific to adipose tissue and absent in forearm muscle.
Takeaway
This study found that a diabetes medication called rosiglitazone helps lower a protein that can cause fat storage in people with diabetes after they eat.
Methodology
A placebo-controlled, crossover, double-blinded study measuring arteriovenous differences in diabetic and healthy men after a mixed meal.
Limitations
Small sample size and only male participants were studied.
Participant Demographics
Nine non-obese healthy men and six diabetic men aged 30-70 years.
Statistical Information
P-Value
p < 0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website